Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMariam NawasMDMichael W. DrazerRLRichard A. Larson

Discussion

Loading...

Member takes

Overview

Phase 1b trial assesses maximal tolerated dose and safety of ruxolitinib with ivosidenib in patients with IDH1 mutations, suggesting potential improvement in outcomes.

Key Points

  • Overall survival in patients with acute myeloid leukemia treated with this regimen may be significantly enhanced through concurrent targeting of hematopoietic stem cells.
  • The study aims to determine the maximal tolerated dose while monitoring for any mutation-related adverse effects present in the cohort.
  • Trial uses a Rolling 6 design to establish the safety profile of the ruxolitinib and ivosidenib combination.
  • Combined JAK1/IDH inhibition could potentially lead to reduced leukemic transformation and improvements in patient outcomes.

Cite This Study

Nawas et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236df97https://doi.org/10.1182/blood-2025-5608
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial2025 · 2 citations
  2. 2PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy2025
  3. 3Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations2025 · 5 citations
  4. 4A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia2025 · 2 citations
  5. 5Ivosidenib combined with venetoclax and azacitidine for the treatment of newly diagnosed IDH1-mutant Acute Myeloid Leukemia: A prospective, two cohorts, multicenter study2025